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Abstract
Aim
Obesity and especially hypertrophy of epicardial adipose tissue accelerate coronary athero-
genesis. We aimed at comparing levels of inflammatory and atherogenic hormones from
adipose tissue in the pericardial fluid and circulation of cardiovascular disease patients.
Methods and Results
Venous plasma (P) and pericardial fluid (PF) were obtained from elective cardiothoracic sur-
gery patients (n = 37). Concentrations of leptin, adipocyte fatty acid-binding protein (A-
FABP) and adiponectin (APN) were determined by enzyme-linked immunosorbent assays
(ELISA). The median concentration of leptin in PF (4.3 (interquartile range: 2.8–9.1) μg/L)
was comparable to that in P (5.9 (2.2–11) μg/L) and these were significantly correlated to
most of the same patient characteristics. The concentration of A-FABP was markedly higher
(73 (28–124) versus 8.4 (5.2–14) μg/L) and that of APN was markedly lower (2.8 (1.7–4.2)
versus 13 (7.2–19) mg/L) in PF compared to P. APN in PF was unlike in P not significantly
related to age, body mass index, plasma triglycerides or coronary artery disease. PF levels
of APN, but not A-FABP, were related to the size of paracardial adipocytes. PF levels of
APN and A-FABP were not related to the immunoreactivity of paracardial adipocytes for
these proteins.
Conclusion
In cardiac and vascular disease patients, PF is enriched in A-FABP and poor in APN. This
adipokine microenvironment is more likely determined by the heart than by the circulation or
paracardial adipose tissue.
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Introduction
Obesity promotes atherosclerosis [1, 2]. Hypertrophic chronically inflamed adipose tissues
produce less signaling molecules with vascular protective actions such as adiponectin (APN)
[3, 4] and more hormones with inflammatory and atherogenic effects such as leptin [5] and
adipocyte fatty acid-binding protein (A-FABP) [6]. The circulating hormonal levels of these
adipokines are likely dominated by the large subcutaneous and abdominal visceral adipose tis-
sue depots [7].
Local accumulation of fat on the outer surface of the heart around the coronary arteries
(epicardial adipose tissue (EAT) [8, 9]) is associated with coronary artery disease (CAD) in not
only obese but also non-obese patients [10–15]. This indicates local paracrine effects of adipo-
kines on coronary arteries [8, 16, 17]. Paired comparisons of EAT with subcutaneous or
abdominal visceral adipose tissue biopsies revealed differences in fatty acid composition [18],
expression and release of chemokines and inflammatory cytokines along with retention of
inflammatory cells [15, 19] and in expression and secretion of adipokines [14, 15, 17, 20].
The composition of the pericardial fluid (PF) surrounding the heart has been proposed to
be comparable to that of the interstitium of the heart [21, 22]. Several angiogenic growth fac-
tors, cytokines, natriuretic peptides and classical vasoactive hormones are present at higher
concentration in the PF than in the circulating plasma (P) of patients with ischemic heart dis-
ease or heart failure [21, 23–25].
Here we tested the hypothesis that the pericardial cavity of cardiovascular disease (CVD)
patients is a unique adipokine microenvironment. To this end we compared the levels of leptin,
A-FABP and APN in the PF and P of cardiothoracic surgery patients.
Material and Methods
Subjects and sample collection
The study was performed in accordance with institutional guidelines and was approved by
the Medical Ethical Committee of the Region of Southern Denmark (S-20100044). Investiga-
tions were performed conform the principles outlined in the Declaration of Helsinki and
informed written consent was obtained from all patients. Between September 2013 and Janu-
ary 2014 consecutive patients who underwent elective coronary artery bypass grafting
(CABG) or cardiac valve replacement surgeries were enrolled. Clinical information was
obtained from the patients’ medical records. On the day before surgery, peripheral venous
blood was drawn into pyrogen-free tubes with K2EDTA as an anticoagulant. Pericardial fluid
(2–5 mL in K2EDTA and aprotinin) and a biopsy from the parietal sheet of the pericardium
(2 x 2 cm) were obtained after median sternotomy and section of the pericardium at outset of
the heart surgeries. The blood and pericardial fluid samples were centrifuged (3220 g for 10
min at 4°C) and the supernatants were stored at -80°C until analysis. The pericardial tissue
biopsies were fixed in neutral buffered formalin for 48 hours at room temperature. Patients
with haemolytic pericardial fluid samples were not further considered. Analyses were limited
to the plasma, pericardial fluid and pericardial tissue biopsy from the same individual
patients (N = 37). Routine plasma analyses for HbA1c, lipids, creatinine and high sensitivity
C-reactive protein (hsCRP) were performed at the Odense University Hospital clinical bio-
chemistry laboratory. Characteristics of the patients were disclosed to the researchers of the
pericardial samples after they finalized their data collection. These characteristics are sum-
marized in Table 1.
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Measurements of adipokine concentrations
The levels of APN and A-FABP in P and PF were measured by the respective sandwich ELISA
kits (Antibody and Immunoassay Services (AIS), The University of Hong Kong, Hong Kong,
China) as previously described [26, 27]. P and PF levels of leptin were determined with an
ELISA kit from Biovendor Laboratories (Brno, Czech Republic) as previously described [27].
All samples were determined in duplicate. For one patient, plasma A-FABP was below the
detection limit.
Table 1. Patient properties, plasma characteristics and prescribed medications.
Property
N 37
CABG / valve / both (%)# 54 / 27 / 19
Age (years) 68 ± 9
Male (%) 84
Smoking Y / F / N (%) 14 / 49 / 38
BMI (kg/m2) 28.8 ± 4.9
Systolic BP (mmHg) 137 ± 21
Diastolic BP (mmHg) 74 ± 13
Ejection fraction (%) 55 (30–70)
Known hypertension (%) 70
Type 2 diabetes (%) 49
Dyslipidemia (%) 81
Plasma concentrations
hsCRP (mg/L) 3.9 (1.8–8.4)
HbA1c (mmol/mol) 40 (35–48)
Total cholesterol (mmol/L) 3.6 (3.2–4.3)
LDL cholesterol (mmol/L) 1.9 (1.6–2.5)
HDL cholesterol (mmol/L) 1.1 (0.9–1.3)
Triglycerides (mmol/L) 1.43 ± 0.63
Creatinine (μmol/L) 90 (78–111)
Medications
Aspirin (%) 65
Other anti-coagulant (%) 32
Statin (%) 76
ACEI /ARB (%) 41 / 16
Beta blocker (%) 60
Calcium antagonist (%) 32
Thiazide diuretic (%) 21
Loop diuretic (%) 27
Aldosterone antagonist (%) 14
Insulin (%) 14
Biguanide (%) 35
Sulfonylurea (%) 8
Categorical data are shown as % of the study group, normally distributed continuous variables as
mean ± SD, non-normally distributed continuous variables as median value (interquartile range).
#, type of surgery. CABG, coronary artery bypass surgery; BMI, body mass index; BP, blood pressure;
hsCRP, high sensitivity C-reactive protein; ACEI/ARB, inhibitor of angiotensin converting enzyme or
antagonist of angiotensin AT1 receptors.
doi:10.1371/journal.pone.0154693.t001
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Western blotting
For detection of different oligomeric complexes of APN, P and PF samples were incubated
with nonreducing sample buffer (1% SDS, 5% glycerol, and 10 mM Tris-HCl (pH 6.8)) at room
temperature for 10 min, separated by 4–20% gradient SDS-PAGE, transferred to polyvinyli-
dene difluoride membranes, and immunoblotted with affinity-purified rabbit anti-human
APN IgG (AIS; 0.2 μg/mL) as we described previously [28]. Based on the ELISA results, sam-
ples containing the same amount of total APN (20 ng) were analyzed by non-reducing
SDS-PAGE and Western blotting for detection of the distribution of oligomers of APN. Quan-
tification was performed by densitometric analysis using ImageJ software (National Institutes
of Health, Bethesda, MA, USA). Increasing concentrations of recombinant human Flag-tagged
APN protein purified from mammalian cells were used to generate the standard curves and to
establish the specificity of the experimental approach in comparison to P and PF samples from
3 randomly selected patients (S1 Fig). Abundance of APN oligomers with molecular
weight> 200 kDa was expressed as % of total APN.
Immunohistochemistry
Presence and distribution of A-FABP and APN in pericardial tissue biopsies were determined
by immunohistochemical (IHC) staining. Paraffin sections (5 μm) of formalin-fixed tissue
were rehydrated and endogenous peroxidase activity was quenched with H2O2 in methanol.
Microwave treatment was used for heat induced antigen retrieval using citrate (for APN) or
Tris-ethylene glycol (TEG, for A-FABP). Sections were incubated overnight at 4°C with pri-
mary monoclonal antibody against APN (1:500, ab22554, ABCAM, Cambridge, UK) or poly-
clonal antibody against A-FABP (1:1200, 11030, AIS, Hong Kong, China) followed by
incubation with goat anti-mouse or goat anti-rabbit secondary antibody, respectively (both
1:1000, P0447 and P0448 resp. Dako, Denmark) for 45 minutes. Colorimetric detection was
completed with 3.3’-diaminobenzidine (DAB). Sections were counterstained with Mayer’s
hematoxylin. Sections without primary antibody served as negative controls. Digital images
were obtained with a microscope (Olympus BX51, Japan) and imaging software (cellSens
Entry, Olympus Corporation, version 1.7). To estimate the size and adipokine content of adi-
pocytes, histological sections were viewed at 10 x magnification and analyzed with ImageJ soft-
ware (version 2.0.0-rc-23; NIH, Bethesda, MD, USA). Adipocyte cross-sectional area was
determined as described by Chen and Farese [29]. The percentage of adipocytes staining for
APN or A-FABP was evaluated in 3–50 square fields (60000 pixels) depending on the thickness
of the paracardial adipose tissue.
Statistics
Continuous variables that were normally distributed are shown as mean ± standard deviation
(SD). Concentrations of biomarkers that were not normally distributed (Shapiro-Wilk normal-
ity test) are shown as median value and interquartile range (IQR). Paired comparisons between
observations in P and PF samples of the same individuals were performed with Wilcoxon
matched-pairs signed rank tests. Associations between the levels of adipokines in PF and P and
between adipokine concentrations and clinical variables were evaluated with Pearson’s correla-
tion tests after Log10 transformation of the data which resulted in normal distribution. Statisti-
cal analyses were performed with GraphPad Prism v6.05 (GraphPad Software Inc, San Diego,
Ca, USA) and IBM SPSS (statistical package for the social sciences softwares; Chicago, Il,
USA). Differences and associations were considered statistically significant at p< 0.05.
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Results
Patient characteristics
Table 1 summarizes demographic, clinical and plasma characteristics of the study group.
Patients were undergoing CABG (54%), cardiac valve replacement (27%) or both (19%) indi-
cating that 73% were suffering from ischemic heart disease due to CAD. As expected, the
majority were elderly overweight males (84%) with a high prevalence of systemic inflammation
(high plasma hsCRP levels), dyslipidemia (81%), hypertension (70%) and type 2 diabetes
(49%) but not overt heart failure or renal failure as judged from ejection fraction and plasma
creatinine. Most had been prescribed a variable combination of anti-coagulant, cholesterol low-
ering, renin angiotensin system inhibitory, anti-hypertensive and anti-diabetic medications.
Pericardial fluid levels of leptin, A-FABP and APN
The concentrations of leptin in PF were comparable to those in the circulating P (4.3 (2.8–9.1)
versus 5.9 (2.2–11) μg/L, p = 0.4344; Fig 1A). A-FABP, on the other hand, was 9 times more
abundant in PF than P (73 (28–124) versus 8.4 (5.2–14) μg/L, p< 0.0001; Fig 1B) while total
APN was 5 times less concentrated in PF than P (2.8 (1.7–4.2) versus 13 (7.2–19) mg/L,
p< 0.0001; Fig 1C; Table 2). As a consequence, the leptin/APN ratio was significantly larger in
PF than P (2.2 (1.2–3.1) versus 0.44 (0.15–0.82) μg/mg; 5 fold). For A-FABP the imbalance was
even more marked. The A-FABP/APN ratio was on average more than 30 times larger in PF
Fig 1. Venous plasma and pericardial fluid concentrations of leptin (left), adipocyte fatty acid-binding protein (A-FABP, middle)
and adiponectin (right) in cardiac and vascular disease patients (n = 36–37). Top, box plots illustrating median values, interquartile
range and range of concentrations compared byWilcoxon matched-pairs signed rank test. Bottom, double logarithmic plots by Pearson’s
correlation illustrating the relationship between pericardial fluid concentrations and circulating levels of the adipokines.
doi:10.1371/journal.pone.0154693.g001
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than in venous P (24 (9.4–70) versus 0.69 (0.35–1.5) μg/mg). Despite marked differences
between the levels of especially A-FABP and APN in PF and P, the concentrations of each of
leptin, A-FABP and APN in PF were positively correlated to those in the venous plasma (Fig
1D–1F).
Western blotting was used to determine the relative abundance of multimers of APN. Typi-
cal results for PF and P from the same individual patients are shown in Fig 2. The contribution
of high molecular weight APN (molecular weight> 200 kDa) to total APN did not differ sig-
nificantly between PF and venous P (29.1 ± 7.5 and 27.4 ± 6.8%, respectively).
Paracardial adipose tissue properties
Fig 3 illustrates structural features and distribution of A-FABP and APN in the parietal sheet of
the pericardium. Mesothelial cells that line the pericardial cavity lay on a thick collagen band.
Abluminally from this structure, a vascular network [30] and paracardial adipose tissue are
located. The thickness of this adipose tissue differed markedly between patients. The median
cross sectional area of paracardial adipocytes was 12 (8.0–17) 102 μm2. With IHC staining,
Table 2. Plasma (P) and pericardial fluid (PF) levels of three adipokines and univariate analyses of their interrelationships and associations with
patient properties.
P Leptin PF Leptin P A-FABP PF A-FABP P APN PF APN
Concentration
μg/L 5.9 4.3 8.4 73###
(2.2–11) (2.8–9.1) (5.2–14) (28–124)
mg/L 13 2.8###
(7.2–19) (1.7–4.2)
Patient property
CABG surgery ns ns ns ns ** ns
Age ns ns ns ns 0.386* ns
BMI 0.588*** 0.498*** ns ns -0.454*** ns
Type 2 diabetes * * ns ns ns ns
Plasma (P)
HbA1c 0.554*** 0.574*** 0.362* ns ns ns
HDL cholesterol ns ns ns ns 0.483** 0.344*
Triglycerides ns ns ns ns -0.454* ns
Creatinine ns 0.408* 0.577*** 0.330* ns ns
Leptin 1 0.807*** 0.565*** ns ns ns
A-FABP 0.565*** 0.573*** 1 0.472*** ns ns
Adiponectin (APN) ns ns ns ns 1 0.583***
Medications
Statin ns ns * ns ns ns
ACEI / ARB ** ** *** * ns ns
Biguanide ns ns ns ns ns *
A-FABP, adipocyte fatty acid-binding protein; APN, total adiponectin; ns, not statistically signiﬁcant; other abbreviations as in Table 1. Concentrations are
shown as median (interquartile range);
###: p < 0.001 versus plasma by Wilcoxon matched-pairs signed rank test.
*, p < 0.05;
**, p < 0.01 and
***, p < 0.001 indicate statistically signiﬁcant correlations to categorical or continuous variables. For continuous variables the Pearson’s correlation
coefﬁcient is shown as well.
doi:10.1371/journal.pone.0154693.t002
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APN was found in parts of the adipose tissue, vascular endothelium (some patients only), and
in collagen-rich regions. A-FABP was located in some of the adipocytes, nerves, arterioles and
capillaries. Mesothelium and arterial smooth muscle cells did not stain for A-FABP or APN.
Presence of detectable A-FABP and APN in adipocytes displayed marked regional heterogene-
ity (Fig 2). The percentage of paracardial adipocytes that was immunoreactive for A-FABP or
APN varied considerably between patients (43 (0.0–94) and 63 (14–100) %), respectively).
Interrelationships and associations
In PF, there were no statistically significant relationships between the levels of the adipokines
investigated while in P the levels of leptin and A-FABP were positively correlated (Table 2). As
expected [1, 31], the circulating level of leptin increased with increasing BMI while the circulat-
ing concentration of APN was inversely correlated to BMI (Table 2). Also in PF, leptin levels
were positively correlated to BMI but the concentrations of APN in PF displayed no significant
relation to BMI.
Table 2 further summarizes associations between the concentrations of adipokines and
patient characteristics listed in Table 1. The concentrations of leptin in both P and PF were
each related to type 2 diabetes, BMI, circulating levels of glycated hemoglobin and to treatment
with an inhibitor of the renin-angiotensin system. For A-FABP in P and PF there were fewer
similarities. This discrepancy between the adipokine concentrations in the two compartments
was even more marked for APN. APN in P, but not PF, was inversely related to CAD, BMI,
and plasma triglycerides and positively correlated to the age of the patients (Table 2).
Fig 2. Representative Western blot images of APNmultimers in pericardial fluid (left) and venous plasma (right) of cardiac and
vascular disease patients. TheWestern blots illustrate the composition of oligomeric complexes of APN in pericardial fluid and plasma
samples from the same 7 individual patients, indicated by numbers 4–10. The contribution of high molecular APN species (> 200 kDa) to
the total concentration of APN was calculated as a percentage as described in the methods section.
doi:10.1371/journal.pone.0154693.g002
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The size of the paracardial adipocytes was significantly larger in type 2 diabetic patients
(13.7 (11.1–18.0) versus 10.2 (6.6–13.1) x 102 μm2, p = 0.038) and in CAD patients (13.6
(10.7–18.0) versus (6.7 (5.9–9.9) x 102 μm2, p = 0.0004) but was not correlated to BMI
(p = 0.642, r = 0.0839), not related to the PF level of A-FABP (p = 0.735, r = 0.0611) and
inversely related to the PF level of APN (p = 0.0364, r = -0.366). Paracardial adipocyte immu-
noreactivity for A-FABP or APN were significantly correlated (p = 0.0469, r = 0.3720) but not
significantly related to adipocyte size (p = 0.352, r = -0.179 and p = 0.223, r = -0.218 respec-
tively) or to the PF concentration of A-FABP or APN (p = 0.507, r = 0.124 and p = 0.460,
r = 0.133, respectively).
Discussion
In pericardial fluid of cardiothoracic surgery patients, the concentration of leptin was compara-
ble but the level of A-FABP markedly higher and that of APN considerably lower than in the
circulating plasma. Leptin levels in pericardial fluid and plasma were correlated to most of the
same patient characteristics while APN in pericardial fluid was unlike in the plasma not corre-
lated to age, body mass index, type 2 diabetes, plasma triglycerides and CAD. The concentra-
tion of APN but not A-FABP in pericardial fluid was related to the size of paracardial
adipocytes, whereas both adipokine concentrations in pericardial fluid were not related to the
immunoreactivity of the adipocytes in the paracardial pericardium. These findings indicate
that the pericardial cavity of cardiovascular disease patients is a pro-inflammatory atherogenic
Fig 3. Representative images of immunohistochemical stainings of adipocyte fatty acid-binding protein (A-FABP; left) and
adiponectin (APN; right) in the parietal pericardium. Top, adjacent sections of the adipose tissue part (A and F) and of the luminal
(mesothelial) side (B and G) from the same biopsy. Bottom, adjacent sections of the biopsy from another patient focusing on the sub-
mesothelial vasculature and its peri-vascular adipose tissue (C-E and H-J). Positive immunoreactivity in the different structures are
indicated as follows: a = adipocytes, n = nerves, c = collagen rich regions, open arrow head = endothelium, small arrows = arterioles and
capillaries. The thick arrow heads indicate mesothelial cells. Scale bars, 100 μm.
doi:10.1371/journal.pone.0154693.g003
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adipokine microenvironment determined by components of the heart rather than by the circu-
lating hormones or paracardial adipose tissue.
Increased risk for metabolic and cardiovascular diseases associated with increased adiposity
[1, 2] stimulated interests in signaling molecules secreted by adipose tissues [4–7]. These adipo-
kines can reach the cardiovascular system as hormones via the circulation and as paracrine
mediators produced by comparatively small adipose tissues that surround the heart and blood
vessels. Hyperleptinemia and hypoadiponectinemia in obesity are strongly associated with type
2 diabetes but only moderately with CAD [32, 33]. Circulating levels of A-FABP increase with
the number of stenotic coronary arteries [34]. On the other hand, the volume of EAT correlates
positively with CAD in not only obese but also non-obese patients [8, 9, 15, 17]. Moreover, sev-
eral classical vasoactive mediators and angiogenic growth factors are more abundant in the
pericardial fluid than in the circulation of ischemic heart disease and heart failure patients [21,
23–25]. For these reasons we performed a small paired cross sectional comparison of concen-
trations of leptin, A-FABP and APN in pericardial fluid and venous plasma. Pericardial fluid
was obtained at outset of coronary artery bypass or cardiac valve replacement surgery where
the parietal pericardium must be opened to gain access to the heart. The characteristics of the
patients that we investigated are comparable to those previously studied with respect to EAT
volume and histology [10, 11, 15, 16, 18, 20] and coronary arteriolar endothelial dysfunction
[35, 36]. Pericardial fluid was compared to a venous blood sample from the day before surgery.
This is justified because earlier studies found no changes in the circulating levels of leptin and
APN and an at most 50% increase of plasma A-FABP during the early steps of cardiothoracic
surgery [37, 38].
Experimental animal evidence (reviewed by Beltowski [5]) links elevations in circulating
levels of the 16 kDa protein leptin via loss of leptin function or leptin resistance to atherogene-
sis and CAD but findings in human patients are less convincing [32]. In line with earlier
reports [5, 31, 39, 40] we observed that in human patients the circulating levels of leptin are
positively correlated to BMI, type 2 diabetes and consequences thereof such as elevated HbA1c,
but not CAD, age or plasma cholesterol and triglycerides. We found that leptin in pericardial
fluid, which to the best of our knowledge was not reported before, is comparable to that in the
venous plasma in terms of not only concentration but also relation to most of the same patient
characteristics. In sharp contrast to leptin, marked quantitative and qualitative differences were
observed for A-FABP and APN. Experimental animal evidence (reviewed by Xu and Van-
houtte [6]) links circulating levels of the 15 kDa protein A-FABP that can be secreted by adipo-
cytes and macrophages, to cardiovascular diseases and findings in patients link it to the
severity of CAD [34] and heart failure [27]. In our paired comparison, A-FABP was nine times
more abundant in pericardial fluid than in circulating plasma and while plasma concentrations
were significantly related to plasma HbA1c and leptin levels and to treatment with statins, peri-
cardial fluid concentrations were not. Experimental evidence (reviewed by Hui et al. [4], Xu
and Vanhoutte [6] and Mattu and Randeva [7]) links reductions of the circulating levels of the
90 (trimeric), 180 (hexameric) and>250 kDa protein APN to endothelial dysfunction and ath-
erogenesis. Again the data available for patients are less convincing [33]. In our study, we con-
firmed the inverse relationships in CVD patients between circulating total APN on the one
hand and CAD, BMI and plasma triglycerides on the other hand and the positive relation
between circulating total APN with age and plasma HDL cholesterol described in earlier
reports [4, 6, 31, 41]. Levels of APN in patient pericardial fluid, which were recently determined
but not correlated to circulating plasma levels [10], were in our hands 4.5 times lower than in
the circulation and not significantly related to any of the factors that seem to govern plasma
APN levels with the exception of a weak association with plasma HDL cholesterol. Combined
our findings indicate that the adipokine composition in pericardial fluid of cardiac and vascular
Adipokines in Pericardial Fluid
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diseases patients differs quantitatively and qualitatively from that in the circulation. For
instance, the leptin/APN and the A-FABP/APN ratio’s that are advanced as powerful diagnos-
tic markers [41–43] are 5 and more than 30 times larger in the local pericardial fluid than in
the circulation, respectively. Although adipokine levels differed markedly between both com-
partments, the circulating and pericardial concentrations of leptin, A-FABP and APN were
strongly correlated. Thus plasma concentrations may be considered in future longitudinal
studies estimating local pericardial changes of adipokines during progression and treatment of
cardiac and coronary artery diseases. These will at best be qualitative in nature and underesti-
mate imbalances between adipokine species.
The pericardial cavity is considered for local treatment of ischemic heart disease and myo-
cardial infarcts by drugs, angiogenic growth factors and stem cells [44, 45]. Control of pericar-
dial fluid composition is however poorly understood. Some authors consider it a protein poor
ultrafiltrate of the plasma [46, 47] while others emphasize similarities to the interstitium of the
heart [21, 22, 47]. Our observations of comparable contributions of low and high molecular
weight APN isoforms in plasma and pericardial fluid and of different pericardial to plasma
ratios for leptin and A-FABP along with earlier findings of elevated levels of lactate dehydroge-
nase (140 kDa) in pericardial fluid [46], are not compatible with the former view. We consid-
ered contributions of the paracardial adipose tissue lining the outer surface of the parietal
pericardium. Paracardial adipocyte size was enlarged in diabetic and CAD patients as previ-
ously reported for epicardial adipocytes [48]. Mean paracardial adipocyte immunoreactivities
for A-FABP and APN were interrelated but not related to adipocyte size in contrast to the neg-
ative associations between the size of subcutaneous and epicardial adipocytes and APN gene
expression previously observed by Bambace et al [48]. We could not observe a significant rela-
tionship between mean paracardial adipocyte immunoreactivity and pericardial fluid levels of
A-FABP and APN. This could indicate that there is no major contribution of paracardial adi-
pose tissue to pericardial fluid levels of adipokines. For the two adipokines that we stained in
parietal pericardium we observed marked regional heterogeneities. Thus in addition to differ-
ences between adipose tissues at different anatomical locations [1, 16–20, 49], adipokine biol-
ogy seems to differ locally within a given adipose tissue. It will be of interest to verify in future
investigations whether these regional heterogeneities are correlated to distances from blood
vessels, capillaries or macrophages, in order to discriminate between differences from perivas-
cular adipose tissue and influences of local oxygen tension and inflammation.
Study Limitations
In this cross sectional investigation of randomly selected cardiothoracic surgery patients a fair
number of strong associations could be observed. The causal nature of these could not be
addressed. The study was too small to appreciate influences of the more rare aspects in the
study population such as female sex and specific medications, or to perform multivariate analy-
sis. No pericardial fluid could be sampled from individuals without CVD or cardiovascular
drug treatments. This may be partly remedied by studies in a sufficiently large relevant experi-
mental animal model [50] and sampling of pericardial fluid from patients undergoing thoracic
surgery for non-CVD [51]. Confounding influences of drugs such as statins and PPARγ ago-
nists that have been observed to influence circulating levels and local expressions of adipokines
[3, 4, 14] might be more difficult to deal with. At this stage we addressed only three proteins
from a broad spectrum of candidate adipokines [1, 7, 17, 31] and future studies may want to
address a broader panel of adipocyte derived signaling molecules. Our suggestions about the
lack of relation between paracardial adipose tissue and pericardial fluid adipokine content are
weakened by the absence of information on paracardial tissue volume which is not part of the
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diagnostics of our elective cardiothoracic surgery patients. More importantly, we lack informa-
tion on epicardial adipose tissue volume [9, 11–13, 15, 16], immunohistochemistry and adipo-
kine secretion [14, 16, 17, 19] to propose this adipose tissue compartment as a determinant of
pericardial fluid adipokine composition. Finally, whether the pericardial fluid adipokine profile
i) represents spillover from the cardiac interstitium with potential for biomarker research of
epicardial adipose tissue effects on CAD and ii) might in itself contribute to coronary athero-
genesis, coronary microvascular dysfunction, arrhythmogenesis and heart failure, will require a
broad variety of dedicated investigations.
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